Verve Ventures

Verve Ventures is a Switzerland-based investment firm focusing on deep-tech startups, providing funding and strategic support to innovative companies across diverse sectors. Founded in 2010 in Baar-Zug, Switzerland, Verve Ventures specializes in investing in deep-tech startups. The firm has completed a total of 3 deals, with a focus on companies that develop groundbreaking technologies. The latest funding round occurred on August 19, 2016, when Verve Ventures raised CHF 3.

5 million in Series B financing from Zürcher Kantonalbank and other investors. This funding has been critical in supporting the growth of their portfolio companies. Verve Ventures specializes in investing in deep-tech startups, focusing on the development of innovative products and services across various sectors. Key offerings from their portfolio include Memo Therapeutics, which develops therapeutic antibodies targeting viral infections and cancer, with its flagship product, potravitug, currently in Phase II clinical trials.

Axelera provides a hardware and software platform for artificial intelligence, enabling data processing at the source of generation. Neustark focuses on utilizing and permanently storing CO2 in concrete, addressing environmental concerns. These products are marketed primarily within the European Union and the broader European landscape, targeting healthcare providers, technology adopters, and construction industries. Verve Ventures operates on a structured investment model involving equity financing and strategic partnerships with its portfolio companies.

Revenue generation for these startups may stem from direct sales of innovative products, subscription services for software solutions, or licensing fees. For instance, companies like Memo Therapeutics could generate revenue through partnerships with healthcare institutions for clinical trials, while Axelera may engage in B2B transactions for its AI platforms. Specific pricing structures are outlined within agreements established between Verve Ventures and its portfolio companies as they align on growth strategies and market entry initiatives. Verve Ventures plans to leverage the CHF 3.

5 million raised in Series B financing to support upcoming product launches and expand into new markets. Recent product developments include advancements in AI technology and therapeutic solutions, with launches targeted within the next two years. The firm is also looking to expand its reach into new geographic regions, particularly targeting markets within northern Europe and the UK by 2024. This funding will aid in enhancing product development efforts and establishing strategic partnerships in these regions.